🇺🇸 Divalproex Sodium (Depakote) in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 10

Most-reported reactions

1. Asthenia — 1 report (10%)
2. Decubitus Ulcer — 1 report (10%)
3. Diabetes Mellitus Inadequate Control — 1 report (10%)
4. Drug Level Above Therapeutic — 1 report (10%)
5. Dyskinesia — 1 report (10%)
6. Gastrointestinal Haemorrhage — 1 report (10%)
7. Infection — 1 report (10%)
8. Influenza Like Illness — 1 report (10%)
9. Myocarditis — 1 report (10%)
10. Overdose — 1 report (10%)

Source database →

Frequently asked questions

Is Divalproex Sodium (Depakote) approved in United States?

Divalproex Sodium (Depakote) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Divalproex Sodium (Depakote) in United States?

National Institute on Drug Abuse (NIDA) is the originator. The local marketing authorisation holder may differ — check the official source linked above.